Page last updated: 2024-08-25

rosiglitazone and Cancer of Prostate

rosiglitazone has been researched along with Cancer of Prostate in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (53.85)	29.6817
2010's	5 (38.46)	24.3611
2020's	1 (7.69)	2.80

Authors

Authors	Studies
Tseng, CH	1
Chen, AM; Cheng, P; Du, Y; Gong, C; Guo, FJ; Liao, H; Qin, L; Ren, Y; Xu, F	1
Chen, AM; Gong, C; Guo, FJ; Liao, H; Qin, L; Ren, Y; Xu, F	1
Akinyeke, TO; Lyles, BE; Moss, PE; Stewart, LV	1
Bläuer, M; Murtola, TJ; Pennanen, P; Syvälä, H; Tammela, TL; Ylikomi, T	1
Boone, B; Cai, H; Fernandez, S; Hayward, SW; He, Y; Jerome, WG; Jiang, M; Magnuson, MA; Matusik, RJ; Roy-Burman, P; Shappell, SB; Yi, Y; Yu, X	1
Lyles, BE; Moss, PE; Stewart, LV	1
Abdel-Mageed, AB; Akingbemi, B; Bartol, F; Braden, T; Dennis, J; Hazi, A; Judd, R; Mansour, M; Morrison, E; Napier, I; Schwartz, D	1
Iyengar, S; Peehl, DM; Roberts, RL; Shappell, SB; Xu, Y	1
Luo, Z; Ruderman, NB; Saha, AK; Wen, R; Xiang, X	1
George, D; Kantoff, PW; Kaufman, DS; Manola, J; Mueller, E; Oh, WK; Slovin, S; Small, E; Smith, MR; Spiegelman, B	1
Allred, CD; Kilgore, MW; Southard, RC; Talbert, DR; Wang, X	1
Boeglin, WE; Brash, AR; Case, T; Dubois, RN; Gupta, RA; Jack, GS; Manning, S; Matusik, RJ; Price, J; Schneider, C; Shappell, SB; Wheeler, TM; Whitehead, R	1

Trials

1 trial(s) available for rosiglitazone and Cancer of Prostate

Article	Year
Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer, 2004, Oct-01, Volume: 101, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Humans; Hypoglycemic Agents; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome	2004

Article

Year

Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy.

Cancer, 2004, Oct-01, Volume: 101, Issue:7

Topics: Adult; Aged; Aged, 80 and over; Humans; Hypoglycemic Agents; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Treatment Outcome

2004

Other Studies

12 other study(ies) available for rosiglitazone and Cancer of Prostate

Article	Year
Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients. Frontiers in endocrinology, 2023, Volume: 14 Topics: Adult; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Male; Propensity Score; Prostatic Neoplasms; Rosiglitazone	2023
Peroxisome proliferator-activated receptor γ ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Molecular medicine reports, 2014, Volume: 10, Issue:1 Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Down-Regulation; Humans; Ligands; Male; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphorylation; PPAR gamma; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Recombinant Proteins; Rosiglitazone; Signal Transduction; Thiazolidinediones; Vascular Endothelial Growth Factor A	2014
Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis. Molecular medicine reports, 2014, Volume: 10, Issue:2 Topics: Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Humans; Male; Phosphatidylinositol 3-Kinases; PPAR gamma; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; RNA, Messenger; Rosiglitazone; Thiazolidinediones	2014
Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell cycle (Georgetown, Tex.), 2009, Jan-15, Volume: 8, Issue:2 Topics: Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Humans; Male; PPAR gamma; Prostatic Neoplasms; RNA, Small Interfering; Rosiglitazone; Signal Transduction; Thiazolidinediones	2009
Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. The Prostate, 2009, Jun-15, Volume: 69, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cell Division; Cell Line, Transformed; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Growth Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Prostate; Prostatic Neoplasms; Rosiglitazone; Simvastatin; Thiazolidinediones	2009
Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy. Cell death and differentiation, 2010, Volume: 17, Issue:3 Topics: Animals; Autophagy; Cell Line; Epithelial Cells; Gene Expression Profiling; Hypoglycemic Agents; Male; Mice; Mice, SCID; Mice, Transgenic; Molecular Sequence Data; Phenotype; PPAR gamma; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Protein Isoforms; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transplantation, Heterologous	2010
The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells. Experimental cell research, 2010, Dec-10, Volume: 316, Issue:20 Topics: Androgen-Binding Protein; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dihydrotestosterone; Gene Expression; Genes, Reporter; Humans; Hypoglycemic Agents; Male; Mutation; Neoplasms, Hormone-Dependent; PPAR gamma; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Transfection	2010
Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. International journal of oncology, 2011, Volume: 38, Issue:2 Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Survival; Chromans; Enzyme-Linked Immunosorbent Assay; Fatty Acid Synthase, Type I; Humans; Hypoglycemic Agents; Male; Neoplasms, Hormone-Dependent; PPAR gamma; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Sterol Regulatory Element Binding Protein 1; Thiazolidinediones; Troglitazone; Tumor Cells, Cultured; Vasodilator Agents	2011
Primary culture model of peroxisome proliferator-activated receptor gamma activity in prostate cancer cells. Journal of cellular physiology, 2003, Volume: 196, Issue:1 Topics: Adenocarcinoma; Cell Division; Gene Expression Regulation, Neoplastic; Humans; Male; Phenotype; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Tumor Cells, Cultured	2003
AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochemical and biophysical research communications, 2004, Aug-13, Volume: 321, Issue:1 Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Cell Division; Cell Line, Tumor; Cell Survival; Enzyme Activation; Humans; Hypoglycemic Agents; Male; Multienzyme Complexes; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Ribonucleotides; Rosiglitazone; Thiazolidinediones	2004
PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. The Journal of nutrition, 2008, Volume: 138, Issue:2 Topics: Anilides; Cell Proliferation; Colonic Neoplasms; Eicosapentaenoic Acid; Gene Expression Regulation; HT29 Cells; Humans; Male; PPAR gamma; Prostatic Neoplasms; Protein Binding; Response Elements; Rosiglitazone; Thiazolidinediones	2008
15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer research, 2001, Jan-15, Volume: 61, Issue:2 Topics: Agar; Arachidonate 15-Lipoxygenase; Blotting, Northern; Catalysis; Cell Division; Culture Media; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Hydroxyeicosatetraenoic Acids; Isoenzymes; Luciferases; Male; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Tumor Cells, Cultured	2001